Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for various indications, such as proteinuria, multiple sclerosis, infantile spasms, ophthalmic, neuromuscular disorders, dermatomyositis, polymyositis, rheumatology, and pulmonology; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; Therakos, an immunotherapy treatment platform; and Amitiza for the treatment of chronic idiopathic constipation. The company is also developing StrataGraft, which is in Phase III and II clinical development for the treatment of burns; terlipressin for the treatment of hepatorenal syndrome; MNK-1411 for the treatment of Duchenne muscular dystrophy; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative fatal disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. Mallinckrodt public limited company markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company is based in Staines-Upon-Thames, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:MNK
CUSIPN/A
Phone44-0-17-8463-6700
Debt
Debt-to-Equity Ratio0.98
Current Ratio2.27
Quick Ratio2.06
Price-To-Earnings
Trailing P/E Ratio3.96
Forward P/E Ratio4.42
P/E Growth0.49
Sales & Book Value
Annual Sales$3.22 billion
Price / Sales0.77
Cash Flow$16.1967 per share
Price / Cash1.83
Book Value$68.65 per share
Price / Book0.43
Profitability
EPS (Most Recent Fiscal Year)$7.49
Net Income$2.13 billion
Net Margins59.85%
Return on Equity10.39%
Return on Assets4.22%
Miscellaneous
Employees3,900
Outstanding Shares83,210,000
Market Cap$2.48 billion
Mallinckrodt (NYSE:MNK) Frequently Asked Questions
What is Mallinckrodt's stock symbol?
Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."
How will Mallinckrodt's stock buyback program work?
Mallinckrodt declared that its Board of Directors has approved a share buyback plan on Sunday, April 9th 2017, which authorizes the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 18.5% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board believes its stock is undervalued.
How were Mallinckrodt's earnings last quarter?
Mallinckrodt PLC (NYSE:MNK) issued its quarterly earnings data on Tuesday, August, 7th. The company reported $1.78 earnings per share for the quarter, topping analysts' consensus estimates of $1.48 by $0.30. The firm had revenue of $631.70 million for the quarter, compared to analyst estimates of $621.15 million. Mallinckrodt had a return on equity of 10.39% and a net margin of 59.85%. View Mallinckrodt's Earnings History.
When is Mallinckrodt's next earnings date?
What guidance has Mallinckrodt issued on next quarter's earnings?
Mallinckrodt updated its FY18 earnings guidance on Tuesday, August, 7th. The company provided EPS guidance of $6.50-6.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.23.
What price target have analysts set for MNK?
20 brokerages have issued 12 month price targets for Mallinckrodt's stock. Their predictions range from $15.00 to $58.00. On average, they anticipate Mallinckrodt's share price to reach $31.5263 in the next year. This suggests a possible upside of 6.4% from the stock's current price. View Analyst Price Targets for Mallinckrodt.
What is the consensus analysts' recommendation for Mallinckrodt?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last year. There are currently 3 sell ratings, 12 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mallinckrodt.
What are Wall Street analysts saying about Mallinckrodt stock?
Here are some recent quotes from research analysts about Mallinckrodt stock:
- 1. According to Zacks Investment Research, "The year 2018 is expected to be a transformative year for Mallinckrodt as the company strives to revive its product portfolio/pipeline. The hospital franchise (Inomax and Ofirmev) has gained traction which is positively impacting sales. The company also upped its annul guidance. The Sucampo buyout will diversify the company’s portfolio considering Amitiza’s potential. The company is currently streamlining its business to focus better on its innovative medicines and therapies like terlipressin and StrataGraft. The recent restructuring efforts are encourgaing as the company has been in troubled waters for quite some time now. However, sales of Acthar continue to decline due to the residual impact of patient withdrawal issues thereby adversely impacting the top-line as the drug is the lead product of the company. The CRL for stannsoporfin was disappointing. Shares have outperformed the industry in the year so far." (9/6/2018)
- 2. Canaccord Genuity analysts commented, "We were pleasantly surprised by Mallinckrodt’s 2Q/18 beat and raise last week as the story continues to evolve toward higher pipeline science and away from Acthar- related drama. However, with strong momentum behind MNK shares of late, we remain concerned about external forces on Acthar or internal pipeline setbacks potentially squelching momentum in the story." (8/13/2018)
- 3. Cantor Fitzgerald analysts commented, ". Post a beat and raise quarter, we are reiterating our OW rating and $42 12-month price target for MNK shares. We believe that concerns regarding its long-term growth potential are overdone and that the company gets little-to-no credit for its pipeline. Therefore, upward earnings revisions and multiple expansion in 2020+ could drive the shares higher, in our view. MNK shares are trading +23% intraday." (8/7/2018)
Are investors shorting Mallinckrodt?
Mallinckrodt saw a decline in short interest during the month of August. As of August 31st, there was short interest totalling 20,778,208 shares, a decline of 15.3% from the August 15th total of 24,536,840 shares. Based on an average trading volume of 2,875,652 shares, the days-to-cover ratio is presently 7.2 days. Approximately 25.4% of the company's shares are sold short. View Mallinckrodt's Current Options Chain.
Who are some of Mallinckrodt's key competitors?
Some companies that are related to Mallinckrodt include Alnylam Pharmaceuticals (ALNY), Beigene (BGNE), Bausch Health Companies (BHC), Valeant Pharmaceuticals (VRX), Amneal Pharmaceuticals (AMRX), Ionis Pharmaceuticals (IONS), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), GALAPAGOS NV/S (GLPG), Ligand Pharmaceuticals (LGND), United Therapeutics (UTHR), FibroGen (FGEN) and Loxo Oncology (LOXO).
Who are Mallinckrodt's key executives?
Mallinckrodt's management team includes the folowing people:
- Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 57)
- Mr. Matthew K. Harbaugh, Exec. VP & CFO (Age 48)
- Dr. Frank Scholz, Exec. VP and Chief Operations & Digital Innovation Officer (Age 49)
- Mr. Hugh M. O'Neill, Exec. VP & Chief Commercial Officer (Age 55)
- Ms. Kathleen A. Schaefer, Sr. VP, Principal Accounting Officer & Corp. Controller
Has Mallinckrodt been receiving favorable news coverage?
News headlines about MNK stock have been trending somewhat positive this week, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mallinckrodt earned a coverage optimism score of 0.18 on Accern's scale. They also gave media stories about the company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Mallinckrodt.
Who are Mallinckrodt's major shareholders?
Mallinckrodt's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.61%), Scopia Capital Management LP (9.22%), Dimensional Fund Advisors LP (5.32%), Miller Value Partners LLC (4.01%), LSV Asset Management (3.22%) and FMR LLC (2.78%). Company insiders that own Mallinckrodt stock include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, James E Flynn, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Institutional Ownership Trends for Mallinckrodt.
Which major investors are selling Mallinckrodt stock?
MNK stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Scopia Capital Management LP, Connor Clark & Lunn Investment Management Ltd., Schroder Investment Management Group, Schroder Investment Management Group, SG Americas Securities LLC, Trexquant Investment LP and FMR LLC. View Insider Buying and Selling for Mallinckrodt.
Which major investors are buying Mallinckrodt stock?
MNK stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Miller Value Partners LLC, Northern Trust Corp, First Trust Advisors LP, Dimensional Fund Advisors LP, Commonwealth Bank of Australia, Eqis Capital Management Inc. and Royce & Associates LP. Company insiders that have bought Mallinckrodt stock in the last two years include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Insider Buying and Selling for Mallinckrodt.
How do I buy shares of Mallinckrodt?
Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mallinckrodt's stock price today?
One share of MNK stock can currently be purchased for approximately $29.64.
How big of a company is Mallinckrodt?
Mallinckrodt has a market capitalization of $2.48 billion and generates $3.22 billion in revenue each year. The company earns $2.13 billion in net income (profit) each year or $7.49 on an earnings per share basis. Mallinckrodt employs 3,900 workers across the globe.
How can I contact Mallinckrodt?
Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]
MarketBeat Community Rating for Mallinckrodt (NYSE MNK)
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe MNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
